Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting
CONCLUSION: This study shows benefit in real-world outcomes of venetoclax+HMAs relative to HMA monotherapy in patients with newly diagnosed AML, using a predominantly community-based database.PMID:36925388 | DOI:10.1016/j.clml.2023.02.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 16, 2023 Category: Cancer & Oncology Authors: Anda Gershon Esprit Ma Tao Xu Melissa Montez Kiran Naqvi Grace Ku Wendy Wei-Han Cheng Evelyn M Flahavan Vamsi Kota Daniel R Greenwald Source Type: research
First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium
Clin Lymphoma Myeloma Leuk. 2023 Feb 3:S2152-2650(23)00035-6. doi: 10.1016/j.clml.2023.01.016. Online ahead of print.ABSTRACTAlthough the availability of effective novel treatments has positively impacted the quality of life and survival of newly diagnosed multiple myeloma (MM) patients, benefits in the transplant ineligible MM population may be limited by functional/frailty status. The Canadian Myeloma Research Group Consensus Guideline Consortium proposes consensus recommendations for the first-line treatment of transplant ineligible MM. To address the needs of physicians and people diagnosed with MM, this document furth...
Source: Clinical Lymphoma and Myeloma - March 16, 2023 Category: Cancer & Oncology Authors: Julie C ôté Rami Kotb Debra J Bergstrom Richard LeBlanc Hira S Mian Ibraheem Othman Martha L Louzada Source Type: research
SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions
Clin Lymphoma Myeloma Leuk. 2023 Feb 3:S2152-2650(23)00034-4. doi: 10.1016/j.clml.2023.01.017. Online ahead of print.ABSTRACTDespite continued advances that have led to improved survival of patients with multiple myeloma (MM) over the years, MM remains largely incurable with overall survival in patients who have progressed after proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody therapy measured in months. Better understanding of the immunopathology of MM has led to the discovery of newer treatment targets like B-cell maturation antigen (BCMA). BCMA is a tumor necrosis factor receptor superfamil...
Source: Clinical Lymphoma and Myeloma - March 16, 2023 Category: Cancer & Oncology Authors: Eden Biltibo Jesus G Berdeja Source Type: research
Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting
CONCLUSION: This study shows benefit in real-world outcomes of venetoclax+HMAs relative to HMA monotherapy in patients with newly diagnosed AML, using a predominantly community-based database.PMID:36925388 | DOI:10.1016/j.clml.2023.02.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 16, 2023 Category: Cancer & Oncology Authors: Anda Gershon Esprit Ma Tao Xu Melissa Montez Kiran Naqvi Grace Ku Wendy Wei-Han Cheng Evelyn M Flahavan Vamsi Kota Daniel R Greenwald Source Type: research
First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium
Clin Lymphoma Myeloma Leuk. 2023 Feb 3:S2152-2650(23)00035-6. doi: 10.1016/j.clml.2023.01.016. Online ahead of print.ABSTRACTAlthough the availability of effective novel treatments has positively impacted the quality of life and survival of newly diagnosed multiple myeloma (MM) patients, benefits in the transplant ineligible MM population may be limited by functional/frailty status. The Canadian Myeloma Research Group Consensus Guideline Consortium proposes consensus recommendations for the first-line treatment of transplant ineligible MM. To address the needs of physicians and people diagnosed with MM, this document furth...
Source: Clinical Lymphoma and Myeloma - March 16, 2023 Category: Cancer & Oncology Authors: Julie C ôté Rami Kotb Debra J Bergstrom Richard LeBlanc Hira S Mian Ibraheem Othman Martha L Louzada Source Type: research
